Statins and stroke: Potential mechanisms for neurovascular protection;Estatinas y accidente cerebrovascular: Posibles mecanismos de acción de la protección neurovascular

Revista de Neurologia

Volumn 51, Issue 9, 2010, Pages 551-560

  Fonseca, Francisco A H ^a   França, Carolina N ^a   Póvoa, Rui M S ^a   Izar, Maria Cristina O ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Blood pressure; Endothelial progenitor cells; Hemostasis; Inflammation; Statins; Stroke

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

BRAIN ISCHEMIA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG ACTIVITY; HEMOSTASIS; HUMAN; META ANALYSIS; NEUROPROTECTION; REVIEW; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE;

EID: 78649884740     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5109.2010430     Document Type: Review

References (71)

1. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
2. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117-25.
3. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-59.
4. Everett BM, Glyn RJ, MacFadyen JG, Ridker PM. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circulation 2010; 121: 143-50.
5. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet 2009; 8: 453-63.
6. Bobadilla JF, Moreno R, Fernández C, Martínez A, Sánchez-Maestre C, Ezpeleta-Echevarri D. Efecto del tratamiento intensivo con atorvastatina frente a dosis estándar de estatinas en el riesgo de ictus de pacientes con enfermedad coronaria previa. Metaanálisis de cinco ensayos aleatorizados con 25.709 pacientes. Rev Neurol 2009; 48: 561-5.
7. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989; 320: 904-10.
8. Lindenstrøm E, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. BMJ 1994; 309: 11-5.
9. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008; 300: 2142-52.
10. Berger K, Schulte H, Stögbauer F, Assmann G. Incidence and risk factors for stroke in an occupational cohort: the PROCAM Study. Prospective Cardiovascular Muenster Study. Stroke 1998; 29: 1562-6.
11. Sillesen H, Amarenco P, Hennerici MG, Callahan A, Goldstein LB, Zivin J, et al. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2008; 39: 3297-302.
12. Amarenco P, Goldstein LB, Callahan III A, Sillesen H, Hennerici MG, O'Neill BJ, et al. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis 2009; 204: 515-20.
13. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-503.
14. Libby P, Schoenbeck U, Mach F, Selwyn AP, Ganz P. Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization. Am J Med 1998; 104: 14-8S.
15. Thim T, Hagensen MK, Bentzon JF, Falk E. From vulnerable plaque to atherothrombosis. J Intern Med 2008; 263: 506-16.
16. Libby P. Atherosclerosis: disease biology affecting the coronary vasculature. Am J Cardiol 2006; 98: 3-9.
17. Libby P. The molecular mechanisms of the thrombotic complications of atherosclerosis. J Intern Med 2008; 263: 517-27.
18. Ambrose JA, Fuster V. The risk of coronary occlusion is not proportional to the prior severity of coronary stenoses. Heart 1998; 79: 3-4. (Pubitemid 28179050)
19. Sadat U, Li ZY, Young VE, Graves MJ, Boyle JR, Warburton EA, et al. Finite element analysis of vulnerable atherosclerotic plaques: a comparison of mechanical stresses within carotid plaques of acute and recently symptomatic patients with carotid artery disease. J Neurol Neurosurg Psychiatry 2010; 81: 286-9.
20. Staub D, Patel MB, Tibrewala A, Ludden D, Johnson M, Espinosa P, et al. Vasa vasorum and plaque neovascularization on contrast-enhanced carotid ultrasound imaging correlates with cardiovascular disease and past cardiovascular events. Stroke 2010; 41: 41-7.
21. Hellings WE, Peeters W, Moll FL, Piers SR, van Setten J, Van der Spek PJ, et al. Composition of carotid atherosclerotic plaque is associated with cardiovascular outcome: a prognostic study. Circulation 2010; 121: 1941-50.
22. Uchiyama S, Goto S, Matsumoto M, Nagai R, Origasa H, Yamazaki T, et al. Cardiovascular event rates in patients with cerebrovascular disease and atherothrombosis at other vascular locations: results from 1-year outcomes in the Japanese REACH Registry. J Neurol Sci 2009; 287: 45-51.
23. Ladd SC, Debatin JF, Stang A, Bromen K, Moebus S, Nuefer M, et al. Whole-body MR vascular screening detects unsuspected concomitant vascular disease in coronary heart disease patients. Eur Radiol 2007; 17: 1035-45.
24. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54: 2129-38.
25. Hermansson A, Ketelhuth DF, Strodthoff D, Wurm M, Hansson EM, Nicoletti A, et al. Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. J Exp Med 2010; 207: 1081-93.
26. Santos AO, Fonseca FA, Fischer SM, Monteiro CM, Brandão SA, Póvoa RM, et al. High circulating autoantibodies against human oxidized low-density lipoprotein are related to stable and lower titers to unstable clinical situation. Clin Chim Acta 2009; 406: 113-8.
27. Brandão SA, Izar MC, Fischer SM, Santos AO, Monteiro CM, Póvoa RM, et al. Early increase in autoantibodies against human oxidized low-density lipoprotein in hypertensive patients after blood pressure control. Am J Hypertens 2010; 23: 208-14.
28. Chapman MJ. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention. Pharmacol Ther 2007; 113: 184-96.
29. Shah P. Inflammation and plaque vulnerability. Cardiovasc Drugs Ther 2009; 23: 31-40.
30. Okazaki M, Iwasaki Y, Jing H, Nishiyama M, Taguchi T, Tsugita M, et al. Insulin enhancement of cytokine-induced coagulation/inflammation-related gene transcription in hepatocytes. Endocr J 2008; 55: 967-75.
31. Churdchomjan W, Kheolamai P, Manochantr S, Tapanadechopone P, Tantrawatpan C, U-Pratya Y, et al. Comparison of endothelial progenitor cell function in type 2 diabetes with good and poor glycemic control. BMC Endocr Disord 2010; 10: 5.
32. Giannotti G, Doerries C, Mocharla PS, Mueller MF, Bahlmann FH, Horvàth T, et al. Impaired endothelial repair capacity of early endothelial progenitor cells in prehypertension: relation to endothelial dysfunction. Hypertension 2010; 55: 1389-97.
33. Keymel S, Kalka C, Rassaf T, Yeghiazarians Y, Kelm M, Heiss C. Impaired endothelial progenitor cell function predicts age-dependent carotid intimal thickening. Basic Res Cardiol 2008; 103: 582-6.
34. Fadini GP, Agostini C, Sartore S, Avogaro A. Endothelial progenitor cells in the natural history of atherosclerosis. Atherosclerosis 2007; 194: 46-54. (Pubitemid 47464318)
35. Chen JZ, Zhang FR, Tao QM, Wang XX, Zhu JH, Zhu JH. Number and activity of endothelial progenitor cells from peripheral blood in patients with hypercholesterolaemia. Clin Sci (Lond) 2004; 107: 273-80.
36. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001; 292: 1160-4.
37. Istvan ES. Statin inhibition of HMG-CoA reductase: a 3-dimensional view. Atheroscler Suppl 2003; 4: 3-8.
38. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res 2005; 97: 1232-5.
39. Zhou Q, Liao JK. Rho kinase: an important mediator of atherosclerosis and vascular disease. Curr Pharm Des 2009; 15: 3108-15.
40. Zeoli A, Dentelli P, Brizzi MF. Endothelial progenitor cells and their potential clinical implication in cardiovascular disorders. J Endocrinol Invest 2009; 32: 370-82.
41. Hoenig MR, Bianchi C, Rosenzweig A, Sellke FW. Decreased vascular repair and neovascularization with ageing: mechanisms and clinical relevance with an emphasis on hypoxia-inducible factor-1. Curr Mol Med 2008; 8: 754-67.
42. Hoenig MR, Bianchi C, Sellke FW. Hypoxia inducible factor-1 alpha, endothelial progenitor cells, monocytes, cardiovascular risk, wound healing, cobalt and hydralazine: a unifying hypothesis. Curr Drug Targets. 2008; 9: 422-35.
43. Hristov M, Schmitz S, Schuhmann C, Leyendecker T, Von Hundelshausen P, Krötz F, et al. An optimized flow cytometry protocol for analysis of angiogenic monocytes and endothelial progenitor cells in peripheral blood. Cytometry A 2009; 75: 848-53.
44. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89: e1-7.
45. Herbrig K, Pistrosch F, Oelschlaegel U, Wichmann G, Wagner A, Foerster S, et al. Increased total number but impaired migratory activity and adhesion of endothelial progenitor cells in patients on long-term hemodialysis. Am J Kidney Dis 2004; 44: 840-9.
46. Salven P, Mustjoki S, Alitalo R, Alitalo K, Rafii S. VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood 2003; 101: 168-72.
47. Quirici N, Soligo D, Caneva L, Servida F, Bossolasco P, Deliliers GL. Differentiation and expansion of endothelial cells from human bone marrow CD133(+) cells. Br J Haematol 2001; 115: 186-94.
48. Kunz GA, Liang G, Cuculi F, Gregg D, Vata KC, Shaw LK, et al. Circulating endothelial progenitor cells predict coronary artery disease severity. Am Heart J 2006; 152: 190-5.
49. Yip HK, Chang LT, Chang WN, Lu CH, Liou CW, Lan MY, et al. Level and value of circulating endothelial progenitor cells in patients after acute ischemic stroke. Stroke 2008; 39: 69-74.
50. Kunz GA, Liang G, Cuculi F, Gregg D, Vata KC, Shaw LK, et al. Circulating endothelial progenitor cells predict coronary artery disease severity. Am Heart J 2006; 152: 190-5.
51. Sobrino T, Hurtado O, Moro MA, Rodríguez-Yáñez M, Castellanos M, Brea D, et al. The increase of circulating endothelial progenitor cells after acute ischemic stroke is associated with good outcome. Stroke 2007; 38: 2759-64.
52. Taguchi A, Matsuyama T, Moriwaki H, Hayashi T, Hayashida K, Nagatsuka K, et al. Circulating CD34-positive cells provide an index of cerebrovascular function. Circulation 2004; 109: 2972-5.
53. Ghani U, Shuaib A, Salam A, Nasir A, Shuaib U, Jeerakathil T, et al. Endothelial progenitor cells during cerebrovascular disease. Stroke 2005; 36: 151-3.
54. Taguchi A, Soma T, Tanaka H, Kanda T, Nishimura H, Yoshikawa H, et al. Administration of CD 34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest 2004; 114: 330-8.
55. Alam MM, Mohammad AA, Shuaib U, Ghani U, Schwindt B, Todd KG, et al. Homocysteine reduces endothelial progenitor cells in stroke patients through apoptosis. J Cereb Blood Flow Metab 2009; 29: 157-65.
56. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005; 111: 2356-63.
57. Spadaccio C, Pollari F, Casacalenda A, Alfano G, Genovese J, Covino E, et al. Atorvastatin increases the number of endothelial progenitor cells after cardiac surgery: a randomized control study. J Cardiovasc Pharmacol 2010; 55: 30-8.
58. Schmidt-Lucke C, Fichtlscherer S, Rössig L, Kämper U, Dimmeler S. Improvement of endothelial damage and regeneration indexes in patients with coronary artery disease after 4 weeks of statin therapy. Atherosclerosis 2010; 211: 249-54.
59. Lawes CM, Vander Hoorn S, Rodgers A, International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371: 1513-8.
60. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13. (Pubitemid 35472129)
61. Lakhan SE, Sapko MT. Blood pressure lowering treatment for preventing stroke recurrence: a systematic review and meta-analysis. Intern Arch Med 2009; 2: 30.
62. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305-15.
63. Mancia G, Grassi G. Secondary prevention of stroke: old and new evidence. Aging Clin Exp Res 2002; 14: 216-20.
64. Strazzullo P, Kerry SM, Barbato A, Versiero M, D'Elia L, Cappuccio FP. Do statins reduce blood pressure? A metaanalysis of randomized controlled trials. Hypertension 2007; 49: 792-8.
65. Golomb BA, Dismdale JE, White HL, Ritchie JB, Criqui MH. Reduction in blood pressure with statins: results from the UCSD statin study, a randomized trial. Arch Intern Med 2008; 168: 721-7.
66. Bautista LE. Blood pressure-lowering effects of statins: who benefits? J Hypertens 2009; 27: 1478-84.
67. Koh KK, Quon MJ, Waclawiw MA. Are statins effective for simultaneously treating dyslipidemias and hypertension? Atherosclerosis 2008; 196: 1-8.
68. King DE, Egan BM, Mainous AG 3rd, Geesey ME. Elevation of C-reactive protein in people with prehypertension. J Clin Hypertens (Greenwich) 2004; 6: 562-8.
69. Dauphinot V, Roche F, Kossovsky MP, Schott AM, Pichot V, Gaspoz JM, et al. C-reactive protein implications in new-onset hypertension in a healthy population initially aged 65 years: the Proof study. J Hypertens 2009; 27: 736-43.
70. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100: 2131-4.
71. Manisty C, Mayet J, Tapp RJ, Sever PS, Poulter N, McG Thom SA, et al. Atorvastatin treatment is associated with less augmentation of the carotid pressure waveform in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT). Hypertension 2009; 54: 1009-13.